文献速递肿瘤 PET/CT

68Ga-FAPI PET/CT在28种癌症中的示踪剂摄取

68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.
PubMed 文献 · J Nucl Med · 2019-04-06

该回顾性研究分析了80例经病理证实的原发或转移性肿瘤患者,涵盖28种肿瘤实体,评估68Ga-FAPI PET/CT的肿瘤摄取。结果显示肉瘤、食管癌、乳腺癌、胆管癌和肺癌平均SUVmax最高(>12),而嗜铬细胞瘤、肾细胞癌、分化型甲状腺癌、腺样囊性癌和胃癌摄取最低(平均SUVmax<6)。高摄取和选择性可能为非侵入性肿瘤表征、分期或放射性配体治疗提供新应用。

要点

  • 68Ga-FAPI在肉瘤、食管癌、乳腺癌、胆管癌和肺癌中摄取最高,平均SUVmax>12。
  • 嗜铬细胞瘤、肾细胞癌、分化型甲状腺癌、腺样囊性癌和胃癌摄取最低,平均SUVmax<6。
  • 肌肉和血池背景低(SUVmax<2),高摄取组肿瘤/背景对比度>6倍。

核心结论

  • 多种高发癌症在68Ga-FAPI PET/CT上表现出显著高摄取和图像对比度。
  • 高且相对选择性的肿瘤摄取可能为非侵入性肿瘤表征、分期检查或放射性配体治疗开辟新应用。

研究设计与样本

  • 回顾性识别80例经组织病理学证实的原发肿瘤或转移灶患者,或经影像学明确转移灶且原发灶经组织学证实的患者。
  • 根据个体临床指征(被认为18F-FDG PET/CT或其他影像检查覆盖不足)申请68Ga-FAPI PET/CT扫描。
  • 注射122-312 MBq的68Ga-FAPI-04后1小时进行PET/CT显像。
  • 肿瘤摄取通过SUVmax和SUVmean(60%等轮廓)量化。

主要发现

  • 共评估80例患者,涵盖28种不同肿瘤实体(54个原发肿瘤和229个转移灶)。
  • 平均SUVmax最高(>12)见于肉瘤、食管癌、乳腺癌、胆管癌和肺癌。
  • 平均SUVmax最低(<6)见于嗜铬细胞瘤、肾细胞癌、分化型甲状腺癌、腺样囊性癌和胃癌。
  • 肝细胞癌、结直肠癌、头颈癌、卵巢癌、胰腺癌和前列腺癌的平均SUVmax为中等(SUV 6-12)。
  • 所有肿瘤实体间及实体内部SUV存在差异。

关键数值与推荐

  • 肌肉和血池背景SUVmax<2。
  • 中等摄取组肿瘤/背景对比度超过3倍,高摄取组超过6倍。

临床怎么用

  • 对于18F-FDG PET/CT或其他影像覆盖不足的临床情况,可考虑68Ga-FAPI PET/CT评估肿瘤摄取。
  • 根据肿瘤类型预期摄取程度:肉瘤、食管癌、乳腺癌、胆管癌和肺癌摄取高;嗜铬细胞瘤、肾细胞癌、分化型甲状腺癌、腺样囊性癌和胃癌摄取低。
  • 高摄取和低背景对比度可能适用于非侵入性肿瘤表征、分期或放射性配体治疗筛选。

局限性

  • 回顾性研究设计。
  • 扫描申请基于个体临床指征,可能存在选择偏倚。
  • 未报告诊断准确性、灵敏度或特异性等数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities. Here, we quantify the tumor uptake on 68Ga-FAPI PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Methods:68Ga-FAPI PET/CT scans were requested by various referring physicians according to individual clinical indications that were considered insufficiently covered by 18F-FDG PET/CT or other imaging modalities. All PET/CT was performed 1 h after injection of 122-312 MBq of 68Ga-FAPI-04. We retrospectively identified 80 patients with histopathologically proven primary tumors or metastases or radiologically unequivocal metastatic lesions of histologically proven primary tumors. Tumor uptake was quantified by SUVmax and SUVmean (60% isocontour). Results: Eighty patients with 28 different tumor entities (54 primary tumors and 229 metastases) were evaluated. The highest average SUVmax (>12) was found in sarcoma, esophageal, breast, cholangiocarcinoma, and lung cancer. The lowest 68Ga-FAPI uptake (average SUVmax < 6) was observed in pheochromocytoma, renal cell, differentiated thyroid, adenoid cystic, and gastric cancer. The average SUVmax of hepatocellular, colorectal, head-neck, ovarian, pancreatic, and prostate cancer was intermediate (SUV 6-12). SUV varied across and within all tumor entities. Because of low background in muscle and blood pool (SUVmax < 2), the tumor-to-background contrast ratios were more than 3-fold in the intermediate and more than 6-fold in the high-intensity uptake group. Conclusion: Several highly prevalent cancers presented with remarkably high uptake and image contrast on 68Ga-FAPI PET/CT. The high and rather selective tumor uptake may open up new applications for noninvasive tumor characterization, staging examinations, or radioligand therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019. PMID: 30954939. doi:10.2967/jnumed.119.227967

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。